António Morais
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
António Morais has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Lobo
Department of Urology, Instituto Português de Oncologia do Porto, 4200-072 Porto, Portugal
1 shared publication - Gabriel Faria-Costa
Department of Urology, Unidade Local de Saúde de Matosinhos, 4464-513 Matosinhos, Portugal
1 shared publication - Isaac Braga
Cancer Biology and Epigenetics Group IPO Porto Research Center (GEBC CI‐IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida Porto Portugal
1 shared publication - Jorge Correia
Department of Urology, Centro Hospitalar Universitário do Porto, Porto, Portugal
1 shared publication - José Sanches Magalhães
Department of Urology, Instituto Português de Oncologia do Porto, 4200-072 Porto, Portugal
1 shared publication - João Carvalho
Department of Urology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 20 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6260
Renal Cell Carcinoma with Venous Tumor Thrombus: 15 Years of Experience in an Oncology Center
Background: The purpose of this study is to report the experience of a single Portuguese oncology center in the management of patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT). Methods: This is a retrospective analysis of all patients with RCC and VTT surgically treated in our center between 2008 and 2023. Only patients with VTT up to level III (Mayo Clinic classification) were included. Patient, tumor characteristics and peri-operative outcome data were registered. Administration of systemic therapy was performed upon progression. Survival analysis was conducted with the collected data. Results: A total of 64 patients (n = 16 women) were included in this study. The mean age at diagnosis was 66.3 ± 10.7 years old. The VTT level was 0, I, II and III in 40 (62.5%), 12 (18.7%), 6 (9.4%) and 6 (9.4%) patients, respectively. Nine patients (14.1%) had distant metastasis at diagnosis. No peri-operative deaths occurred, and the major complication rate was 3.1%. Histology revealed 98.4% of clear cell RCC, with sarcomatoid differentiation present in 12.5% of the cases. A negative margin status was achieved in 54 (84.4%) patients. Systemic therapy was administered in 24 (37.5%) patients during follow-up. The median progression-free (PFS), cancer-specific (CSS) and overall (OS) survival were 23, 60 and 48 months, respectively. In multivariable analysis, significant predictors of CSS were tumor size, sarcomatoid differentiation and collecting system invasion. Conclusions: Radical nephrectomy with VTT excision up to level III is a feasible and safe procedure. Patients with large tumor size, sarcomatoid differentiation and collecting system invasion are at the highest risk and should be closely monitored.
- 20 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6260
Open AccessRenal Cell Carcinoma with Venous Tumor Thrombus: 15 Years of Experience in an Oncology Center
Background: The purpose of this study is to report the experience of a single Portuguese oncology center in the management of patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT). Methods: This is a retrospective analysis of all patients with RCC and VTT surgically treated in our center between 2008 and 2023. Only patients with VTT up to level III (Mayo Clinic classification) were included. Patient, tumor characteristics and peri-operative outcome data were registered. Administration of systemic therapy was performed upon progression. Survival analysis was conducted with the collected data. Results: A total of 64 patients (n = 16 women) were included in this study. The mean age at diagnosis was 66.3 ± 10.7 years old. The VTT level was 0, I, II and III in 40 (62.5%), 12 (18.7%), 6 (9.4%) and 6 (9.4%) patients, respectively. Nine patients (14.1%) had distant metastasis at diagnosis. No peri-operative deaths occurred, and the major complication rate was 3.1%. Histology revealed 98.4% of clear cell RCC, with sarcomatoid differentiation present in 12.5% of the cases. A negative margin status was achieved in 54 (84.4%) patients. Systemic therapy was administered in 24 (37.5%) patients during follow-up. The median progression-free (PFS), cancer-specific (CSS) and overall (OS) survival were 23, 60 and 48 months, respectively. In multivariable analysis, significant predictors of CSS were tumor size, sarcomatoid differentiation and collecting system invasion. Conclusions: Radical nephrectomy with VTT excision up to level III is a feasible and safe procedure. Patients with large tumor size, sarcomatoid differentiation and collecting system invasion are at the highest risk and should be closely monitored.